Ritual to relief: ethical frontiers in repurposing psychoactive substances.

Compared with other fields of medicine, drug discovery and development in psychiatry have been relatively underwhelming. The problems seem infinite. Disorders of the mind are highly variable. Symptomatology is wide-ranging and differs significantly between individuals. Classification strategies rely on subjective, imprecise methods. No powerfully singular pathophysiological pathways have been identified, rather inferences are made. The central nervous system is also endlessly complex. Our understanding of the genetic and neural intricacies is embryonic. The brain generates sophisticated patterns of activity and responses that define its spatiotemporal organization. While this reorganizing capacity offers great promise it also leaves us vulnerable. Pathophysiological changes can be progressive and treatment remission remains a significant issue for the majority of psychiatric disorders. Likewise, human behavior is complex and not neatly explained by the sum of its parts. Translating treatment into practice has been incredibly challenging. Pharmacotherapeutic research that traditionally relies on a receptor-ligand model is overly simplistic and does not account for the vast array of possibilities. With no cohesive way to explain disease states or the brain, we are working in the shadows. There is however a growing urgency to uncover novel psychiatric treatments. Mental, neurological, and substance use disorders account for 10% of the global burden of disease, imposing significant economic costs, and are among the leading causes of disability. One in every hundred deaths is by suicide, with its impact reverberating through communities. 1 Furthermore, climate change is expected to provoke both chronic and acute mental health conditions, amplifying the need for innovative solutions. In this context, psychoactive substances, known for their acute, mind-altering capabilities are being increasingly investigated for their therapeutic potential. Many of these substances are plant-derived and have a long history of use in non-medical contexts, seen as either tools for social cohesion or sources of discord, depending on cultural and societal frameworks. In 18th-century Europe, there was a pivotal shift in thinking when the effects of these substances began to be understood less as spiritual or transcendent but rather as having physiological underpinnings. 2 This narrative shift played a crucial role in an evolving understanding of psychoactive substances, which have since navigated a complex and circuitous route, alternatively classified as recreational or medical across different historical phases. With psychiatric disorders and the brain only partially understood, research has been increasingly turning to work in the shadows; revisiting these substances to explore their therapeutic potential, while also challenging the limitations and boundaries of traditional scientific and medical models. Among these substances are psychedelics which in the broadest sense include 5-hydroxytryptamine receptor 2A (5-HT2A) agonists such as lysergic acid diethylamide (LSD), psilocybin and other dimethyltryptamine-containing substances, dissociative anesthetics like ketamine and scopolamine and various other hallucinogens such as ibogaine and salvia divinorium. The amphetamine-derived enactogen, 3,4-methylenedioxymethamphetamine (MDMA), produces some psychedelic-like effects but its hallucinogenic properties are less pronounced. These substances are being investigated as potential treatments for a wide range of conditions including treatment-resistant depression, post-traumatic stress disorder, cancer-related distress, and substance use disorders. Concurrently, stimulants like amphetamines are increasingly prescribed for an expanding attention-deficit and hyperactivity disorder (ADHD) indication and we remain in the very active tail of the widespread opiate prescription experiment. At the risk of following a similar trajectory, cannabis medicines acting on the endocannabinoid system, are already in use for a wide range of conditions including chronic pain, anxiety, and sleep disorders despite a lack of robust evidence for some specific indications. This unique ability to acutely alter the sensorium makes psychoactive substances differ from many established treatments. While a more integrative, nuanced approach is welcome, they demand a distinct kind of scrutiny. They can profoundly impact perception and consciousness and careful consideration of the risks and responsibilities is needed. Potential benefits must be carefully weighed against the risks of misuse, cultural extractionism, and environmental degradation, along with the unintended consequences of integrating these powerful agents into modern therapeutic practices. Providing an exhaustive review of all the nuanced ethical issues facing this group of treatments is nearly impossible. While broader ethical issues apply to all psychiatric treatment and prescribing, this will focus on some of the central and contentious issues these newer pharmacotherapy approaches face, as well as referring to some of the generalities worth highlighting. It will be divided into three sections focusing on psychedelics, followed by cannabis medicines and stimulants with pertinent issues discussed in each group of treatments.

While manipulating brain chemistry offers valuable therapeutic potential, it cannot fully address the complexities of the human mind. Accordingly, searching for pharmacological solutions to the profound and existential challenges people face could erode psychiatric care. Rigorous ethical codes are crucial, but cannot take the place of an active, thoughtful, creative approach to the moral responsibilities clinicians face. These extend beyond simply prescribing. Medically adapted psychoactive substances harbor a potential for mistreatment and misuse affecting not only individuals but also communities. Meanwhile, they also offer the potential for paradigm-shifting changes that could radically progress the field of psychiatry. In holding the potential to cause great harm, they call for an ethically intelligent approach. This means an active process of continuous awareness, ongoing questioning, and personal responsibility alongside international cooperation in ethical oversight. This ethical responsibility will need to straddle both non-medical and medical contexts, acknowledging that some non-medical use is driven by perceived benefit and spiritual intent and is not solely recreational. It perhaps calls us to face these sophisticated problems with sophisticated solutions and accessibility will be a key domain of focus. Relatedly, precision psychiatry should not just focus on individual bodies but also embrace system complexity, acknowledging that people are interconnected and that solutions should be holistic, rather than individualistic.